Key Takeaways:
- CSPC Pharma received USD1.2 billion upfront from AstraZeneca on May 29
- The payment stems from a licensing deal for peptide drug platforms
- Shares rose 2.4%; CLSA rates it outperform with a HKD19 target
Back
CSPC Pharma receives USD1.2 billion upfront from AstraZeneca in licensing deal
CSPC Pharmaceutical Group (01093.HK) received USD1.2 billion upfront from AstraZeneca on May 29 after trading hours, the largest upfront payment in a Chinese pharma licensing deal this year, under a strategic collaboration for long-acting peptide drugs.
"The receipt of the upfront payment will have a positive contribution to the Group's financial position," CSPC Pharma said in an exchange filing.
The payment stems from a research and development collaboration and licensing agreement announced earlier, under which CSPC will use its proprietary long-acting delivery technology platform and peptide drug AI discovery platform to develop innovative long-acting peptide drugs. Shares rose 2.4% on May 29, with short selling volume reaching HKD350.4 million, or 20.2% of turnover. CLSA reiterated its "Conviction List Outperform" rating with a HKD19 price target after CSPC's first-quarter results beat estimates.
The USD1.2 billion upfront payment significantly strengthens CSPC's balance sheet, providing ample liquidity for its pipeline of more than 30 clinical-stage candidates. The deal with AstraZeneca, one of the world's largest drugmakers, validates CSPC's proprietary drug delivery technology and could pave the way for additional licensing partnerships with global pharma companies. Investors will watch for potential milestone payments tied to the collaboration, which could add further upside beyond the upfront sum.
This article is for informational purposes only and does not constitute investment advice.
[1] CSPC PHARMA (01093.HK) Receives USD1.2B Upfront Payment from AstraZeneca, Positive Contribution to Financial Position[2] CSPC PHARMA (01093.HK) Receives USD1.2B Upfront Payment from AstraZeneca, Positive Contribution to Financial PositionFinancial News - AASTOCKS.com[3] CSPC PHARMA (01093.HK) Receives USD1.2B Upfront Payment from AstraZeneca - AASTOCKS.com
